Cargando…
The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895
Autores principales: | Trudeau, Maureen, Fraser, Brent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217326/ https://www.ncbi.nlm.nih.gov/pubmed/37232838 http://dx.doi.org/10.3390/curroncol30050380 |
Ejemplares similares
-
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”
por: Rayson, Daniel, et al.
Publicado: (2023) -
Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
por: Masucci, Lisa, et al.
Publicado: (2017) -
Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example
por: McDonald, Heather, et al.
Publicado: (2016) -
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
por: Rayson, Daniel, et al.
Publicado: (2022) -
Correction: Ratnayake et al. Assessment of Breast Cancer Surgery in Manitoba: A Descriptive Study. Curr. Oncol. 2021, 28, 581–592
por: Ratnayake, Iresha, et al.
Publicado: (2021)